康艾注射液对结直肠癌肝转移介入术后肝功能的影响

Effect of Kang′ai Injection on liver function after colorectal cancer liver metastasis intervention

目的探讨康艾注射液对结直肠癌肝转移患者行肝动脉化疗栓塞介入术(TACE)后肝功能的影响。方法选取2014年1月~2016年12月我院收治的46例结直肠癌肝转移患者作为研究对象,根据入院顺序将其分为对照组和研究组,每组各23例。两组均行TACE,对照组患者单纯行普通护肝治疗,研究组患者在普通护肝治疗的基础上加用康艾注射液。比较两组患者的治疗效果、治疗前后临床主症变化、血清肝功能指标[丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、总胆红素(TBil)、总胆汁酸(TBA)及清蛋白(ALB)]、肿瘤标志物指标[癌胚抗原(CEA)、糖抗原19-9(CA19-9)及甲胎蛋白(AFP)]及Karnofsky(KPS)评分。结果两组患者治疗前的肝区疼痛、发热及黄疸发生率比较,差异无统计学意义(P>0.05);两组患者治疗后的肝区疼痛、发热及黄疸发生率均低于治疗前,且研究组均低于对照组,差异有统计学意义(P<0.05)。治疗后,研究组患者的ALT、AST、TBil、TBA水平均低于对照组,ALB水平高于对照组,差异有统计学意义(P<0.05);两组治疗后的肿瘤标志物指标水平比较,差异无统计学意义(P>0.05)。研究组患者的治疗总有效率(60.9%)高于对照组(52.2%),差异有统计学意义(P<0.05)。两组患者治疗后的KPS评分比较,差异无统计学意义(P>0.05)。结论康艾注射液具有较好的肝功能保护作用,可作为预防结直肠癌肝转移行TACE后肝损害的辅助用药,也能间接提高结直肠癌肝转移的整体治疗效果。

Objective To investigate the effect of Kang′ai Injection on liver function in patients with colorectal cancer liver metastasis after transcatheter arterial chemoembolization(TACE). Methods A total of 46 patients with colorectal cancer liver metastasis who were admitted to our hospital from January 2014 to December 2016 were selected as the research subjects. They were divided into control group and study group according to the order of admission, with 23 cases in each group. Both groups were treated with TACE, patients in the control group received regular liver protection therapy alone, while patients in the study group received Kang′ai Injection on the basis of regular liver protection therapy. The treatment effect, clinical main symptoms, serum liver function indicators(alanine transaminase [ALT], aspartate transaminase [AST], total bilirubin [TBil], total bile acid [TBA] and albumin [ALB]), tumor markers(carcinoembryonic antigen [CEA], carbohydrate antigen 19-9 [CA19-9] and alpha-fetoprotein [AFP]), and Karnofsky(KPS) scores before and after treatment in the two groups were compared. Results There were no significant differences in the incidence rates of pain in the liver area, fever and jaundice before treatment between the two groups of patients(P>0.05).The incidence rates of pain in the liver area, fever and jaundice of the two groups after treatment were lower than those before treatment, and those in the study group were lower than those in the control group, the differences were statistically significant(P<0.05). After treatment, the levels of ALT, AST, TBil, and TBA in the study group were lower than those in the control group, and the ALB level was higher than that in the control group, the differences were statistically significant(P<0.05). There were no significant differences in the levels of tumor markers between the two groups after treatment(P>0.05). The total effective rate of treatment in the study group(60.9%) was higher than that in the control group(52.2%), and the difference was statistically significant(P<0.05). There was no significant difference in KPS score between the two groups after treatment(P>0.05). Conclusion Kang′ai Injection has a better protection of liver function, can be used as an adjunct to prevent colorectal cancer liver metastasis after TACE from liver damage, and can also indirectly improve the overall therapeutic effect of colorectal cancer liver metastasis.